combacte-net Poster

Incidence of Antibiotic-Associated Diarrhea and Clostridium difficile Infection in Europe

26/07/2021

Da Volterra Announces First Patient Randomized in Phase 3 Clinical Trial Evaluating the Gut Microbiome Protector DAV132 in Patients with Hematologic Malignancies

World’s first phase 3 study of a microbiome protector, conducted as part of the European COMBACTE-NET program Consortium of European teams at the van...

19/07/2021

Aridis Pharmaceuticals Announces Exclusive License of suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZeneca

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced that it has entered into an exclusive, worldwide licensing agreement with AstraZeneca (LSE...

22/04/2021

Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial